Best ADC (Antibody-Drug Conjugate) CDMOs in Europe

← All ADC CDMOs Best Clean FDA History Commercial Scale

Region: USA Europe Asia

CDMOs tracked

Fully scored

With FDA records

FDA inspections

EMA/MHRA GMP certs

Warning letters

For European-manufactured adc (antibody-drug conjugate) programs, Charles River Laboratories, AGC Biologics, and SK pharmteco lead CDMO Signal's ranking of adc (antibody-drug conjugate) CDMOs with confirmed European manufacturing sites. Filtered from the global directory of 10 scored adc (antibody-drug conjugate) CDMOs to 6 with European facility presence. EU and UK manufacturing carry specific regulatory considerations for sponsors: EMA and MHRA GMP certification — which contribute directly to the Signal Score's Quality Compliance pillar — are typically required for material supplied to EU/UK trials or commercial markets, and Qualified Person (QP) release is a distinct process step that doesn't apply to US-only manufacturing. Rankings update as new inspection and certificate data enters the platform. Full methodology at cdmosignal.com/methodology.

Antibody-drug conjugates pair a targeting antibody with a cytotoxic payload via a chemical linker — a three-component process that crosses biologics, small-molecule, and HPAPI (high-potency API) disciplines. Manufacturing demands purpose-built containment (typically OEB-5), wet-chemistry linker-payload synthesis, and validated bioconjugation under GMP.

Selecting an ADC CDMO turns on commercial bioconjugation track record, containment level, the linker / payload chemistries already in their book of business (vc, mc, glucuronide; MMAE, MMAF, DM1, DM4, Dxd, calicheamicin, PBDs, etc.), drug-substance + drug-product capability, and clean FDA + EMA/MHRA inspections. The rankings below score each CDMO on FDA inspections, GMP certification, clinical activity, and capacity.

FDA inspection outcomes across these CDMOs: 9 NAI (no action), 14 VAI (voluntary action), 1 OAI (official action). Leading inspection & GMP sites: United States (22), Denmark (18), UNITED KINGDOM (13), Germany (10), UNITED STATES (8).

Last updated 2026-08-01. Sourced from FDA, EMA EudraGMDP, MHRA GMDP, and ClinicalTrials.gov.

#	CDMO	Signal Score	Quality	FDA · GMP	Capacity	Programs
1	CR Charles River Laboratories Newbury Park, CA · Memphis, TN · Keele, UK · Rockville, MD	91.7	98.7	8 insp · 11 GMP	Limited	0 programs
2	AG AGC Biologics Longmont, CO · Milan, IT · Copenhagen, DK · Chiba, JP	80.6	99.9	2 insp · 23 GMP	Available	2 programs
3	SK SK pharmteco Dublin, Ireland. Rancho Cordova, CA. King of Prussia, PA. Houston, TX. Korea. France.	79.5	100.0	—	Available	0 programs
4	Lonza Basel, Switzerland	78.2	95.1	2 insp · 8 GMP	—	1 programs
5	Catalent Bagsværd, Denmark (operating under Novo Holdings)	76.5	79.3	11 insp · 35 GMP	—	0 programs
6	CA Catalent (Novo Holdings) Harmans, MD · Gosselies, BE	75.1	79.3	1 insp · 0 GMP	Available	0 programs
—	Icosagen Tartu, Estonia	Profiled	—	—	—	0 programs
—	Olon Group Rodano (Milan), Italy	Profiled	—	—	—	0 programs
—	Olon Rodano (Milan), Italy	Profiled	—	—	—	0 programs
—	Fermion (Orion Group) Espoo, Finland	Profiled	—	—	—	0 programs
—	Sterling Pharma Solutions Cramlington, United Kingdom	Profiled	—	—	—	0 programs
—	Mabion S.A. Konstantynów Łódźki, Poland	Profiled	—	—	—	0 programs
—	Ardena Ghent, Belgium	Profiled	—	—	—	0 programs
—	EUROAPI Paris, France	Profiled	—	—	—	0 programs
—	Pierre Fabre CDMO Toulouse, France	Profiled	—	—	—	0 programs
—	Curapath Spain (exact city not disclosed publicly)	Profiled	—	—	—	0 programs
—	Biopharma Group Swindon, United Kingdom	Profiled	—	—	—	0 programs
—	SEQENS Pharmaceutical Solutions (broader group) Écully, France	Profiled	—	—	—	0 programs
—	Fresenius Kabi Bad Homburg, Germany	Profiled	—	—	—	0 programs
—	Genmab (via ProfoundBio acquisition) Copenhagen, Denmark	Profiled	—	—	—	0 programs
—	Axplora Raubling, Germany	Profiled	—	—	—	0 programs
—	Novasep Lyon, France	Profiled	—	—	—	0 programs
—	Cerbios-Pharma Lugano, Switzerland	Profiled	—	—	—	0 programs
—	ICROM S.r.l. Concorezzo, Italy	Profiled	—	—	—	0 programs
—	Jetpharma SA Balerna, Switzerland	Profiled	—	—	—	0 programs
—	Almac Group Craigavon, United Kingdom	Profiled	—	—	—	0 programs

How we score CDMOs →

What to evaluate in a ADC (Antibody-Drug Conjugate) CDMO

HPAPI containment

Look for OEB-5 (sub-microgram occupational exposure band) suites for handling cytotoxic payloads end-to-end. Containment maturity is the floor for credible commercial ADC work.

Linker-payload chemistry on file

Match the CDMO's payload + linker experience to your program. MMAE / vc-MMAE is the most common; PBDs, calicheamicin, Dxd-class topoI inhibitors, and TLR agonists each carry distinct handling and analytical demands.

Commercial bioconjugation track record

Has the CDMO conjugated a commercially-approved ADC? Track record on Polivy, Padcev, Trodelvy, Enhertu, Tivdak, Elahere, Adcetris, Mylotarg, Besponsa, Lumoxiti, Blenrep, etc. is a strong qualifying signal.

Integrated DS + DP

Bioconjugation produces ADC drug substance; you'll also need sterile fill-finish for drug product. Confirm whether the CDMO covers both or partners — both routes work, but integrated is faster on transfer.

Regulatory track record

Cross-check FDA 483 history and EMA/MHRA GMP coverage — both shown above and on each profile.

EMA and MHRA regulatory considerations for European-manufactured programs

European manufacturing for biopharma programs typically requires EMA-recognized GMP certification (via the EudraGMDP database) for EU material and MHRA GMP certification for UK material — post-Brexit, these are separate credentials even for CDMOs operating in both. The Signal Score's Quality Compliance pillar weighs EMA + MHRA GMP certificate density directly, so European CDMOs with dense certification typically rank higher on this pillar. Sponsors should verify certificate coverage for the specific manufacturing activity (drug substance vs drug product, dosage form) at the specific facility being considered — GMP certificates are activity-scoped, not blanket.

QP release requirements and how they affect CDMO selection

Every batch of medicinal product supplied to the EU market must be released by a Qualified Person (QP) — a specific regulatory role with statutory responsibility. This adds a process step (and typically a specific QP-service arrangement) that US-only manufacturing does not require. CDMOs with European operations either have in-house QPs (typical for larger diversified players) or coordinate with external QP services. For sponsors running EU trials or supplying EU commercial markets, this is a non-negotiable requirement to plan for. Individual CDMO profile pages capture facility-level detail; QP arrangements specifically are usually confirmed at RFP stage rather than published.

Which European CDMOs also cover FDA (US) regulatory geography?

European CDMOs with US FDA inspection history — indicating US regulatory posture — are candidates for sponsors running programs in both jurisdictions. The Signal Score's Quality Compliance pillar includes FDA inspection classifications, so a European CDMO with a strong FDA record typically ranks higher on that pillar than a European-only competitor. Cross-check with the US region ranking — CDMOs appearing in both rankings have demonstrated regulatory posture across both jurisdictions, which reduces tech-transfer risk for global programs.

ADC (Antibody-Drug Conjugate) CDMOs — Frequently Asked Questions

Who are the top ADC (Antibody-Drug Conjugate) CDMOs?

By CDMO Signal's independent Signal Score, the top-ranked ADC (Antibody-Drug Conjugate) CDMOs include Charles River Laboratories, AGC Biologics, SK pharmteco. See the full ranked table above — scored on FDA, clinical, financial, and capacity data.

How many ADC (Antibody-Drug Conjugate) CDMOs have FDA inspection records?

CDMO Signal tracks 5 ADC (Antibody-Drug Conjugate) CDMOs with FDA inspection records and 77 EMA/MHRA GMP certificates across the group.

What's the difference between an ADC CDMO and a biologics CDMO?

A biologics CDMO makes the naked antibody (drug substance). An ADC CDMO additionally handles the cytotoxic payload synthesis and the bioconjugation step under HPAPI containment. Some large CDMOs (Lonza, Catalent) do both; others specialize in conjugation only and source the antibody from a biologics partner.

Which CDMOs have made commercially-approved ADCs?

Several CDMOs have commercial ADC track records. The rankings above show our scored ADC players — Lonza (Polivy, Padcev), Catalent (multi-program commercial conjugation), Piramal, AGC Biologics, Samsung Biologics, WuXi Biologics, Charles River — with FDA inspection and GMP detail per profile.

What HPAPI containment level should an ADC CDMO have?

OEB-5 (sub-microgram per cubic meter occupational exposure band) is the standard floor for handling MMAE, MMAF, DM1, DM4, Dxd, PBDs, and calicheamicin-class payloads. Some legacy payloads can run in OEB-4 but commercial work is OEB-5.

Related modalities

Biologics / mAb CDMOs Oligonucleotide / ASO CDMOs Recombinant Proteins CDMOs

Other Modalities

AAV CAR-T Lentiviral Cell Therapy mRNA/LNP Plasmid DNA Biologics Oligo/ASO Adenoviral Gene Editing Exosome Recombinant Proteins